Takeda, a Japanese biopharmaceutical firm, on Wednesday said it would hire 750 deeptech professionals in calendar 2025 to be deployed at its newly set-up Innovation Capability Centre (ICC) in ...
Here, we highlight the trends and key deals. The transactions analysed include those in the biopharma industry, as well as consumer and over-the-counter companies, drug delivery technologies ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
In the 10th megaround of 2025, Umoja Biopharma has banked $100 million in a Series C fundraise with an eye to advancing its pipeline of … ...
GeekWire’s startup coverage documents the Pacific Northwest entrepreneurial scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and venture capital ...
Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell therapies into the clinic. Umoja’s only clinical-stage candidate is UB ...
Morgan Stanley estimates that around $175 billion of 2025 U.S. large-cap biopharma revenue – 35% of the total – will go off patent by the end of the decade. To replace that revenue drugmakers ...
It follows a busy week for private financing in biotech, adding to nearly $2 billion worth of investment announced by venture firms tracked by BioPharma Dive since Monday. Tune’s lead therapy, dubbed ...
The company’s launch is backed by an oversubscribed Series A round of $411m co-led by Forbion and General Atlantic. RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures and LYFE Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback